NovoCure Q2 EPS $(0.54) Misses $(0.50) Estimate, Sales $126.05M Beat $124.26M Estimate
Portfolio Pulse from Benzinga Newsdesk
NovoCure (NASDAQ:NVCR) reported Q2 losses of $(0.54) per share, missing the analyst consensus estimate of $(0.50) by 8 percent. This is a 134.78 percent increase in losses from the same period last year. However, the company's quarterly sales of $126.05 million beat the analyst consensus estimate of $124.26 million by 1.44 percent, despite a 10.52 percent decrease from last year.
July 27, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
NovoCure's Q2 earnings missed estimates with increased losses, but sales beat estimates despite a decrease from last year.
NovoCure's increased losses and missed earnings estimates are likely to negatively impact the stock price. However, the fact that sales beat estimates, despite a decrease from last year, may mitigate some of this negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100